Studies of transgenic breast cancer mouse models that have a biallelic Lcn2 deficiency have shown a delay in tumor-formation rates, metastasis, and the number and size of primary tumors compared to normal or Lcn2 heterozygous mice [60,61]. This evidence concerns the gene LCN2 and neoplasm.